Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

All: Brain, nervous system

A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab

The goal of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control glioblastoma. The safety of this drug combination will also be studied.

Status: Accepting New Patients
Principal Investigator: Raizer

A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients with Recurrent Glioblastoma Multiforme

The goal of this research study is to find out if SL-701 is safe and tolerable and what effect it has on brain tumors.

Status: Accepting New Patients
Principal Investigator: Raizer

Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 3 - MEK162 for Patients with RAS/RAF/MEK Activated Tumors Local

The purpose of this clinical trial is to study if MEK162 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a RAS/RAF/MEK activated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.

Status: Accepting New Patients
Principal Investigator: Johnson

Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 4 - LGX818 for Patients with BRAFC600 Mutated Tumors

Researchers want to know if LGX818 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a BRAFV600 activated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.

Status: Accepting New Patients
Principal Investigator: Johnson

Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 2 - Dovitinib for Patients with Tumor Pathway Activations Inhibited by Dovitinib Including Tumors with Mutations or Translocations of FGFR, PDGFR, VEGF, CKIT, FLT3, CSFR1, TRK and RET

Researchers want to know if dovitinib (TKI258) is safe and has beneficial effects in people who have different tumor types (cancer) and/or blood malignancies whose disease progressed after standard treatment.

Status: Accepting New Patients
Principal Investigator: Johnson

A Phase 2, Multicenter, Open-Label Study Of BGJ398 in Patients with Recurrent Resectable or Unresectable Glioblastoma

The main purpose of this study is to find out if BGJ398 is safe and if it is effective in treating glioblastoma.

Status: Accepting New Patients
Principal Investigator: Raizer

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Hitsman

Phase III trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup trial.

The purpose of this study is to determine whether the addition of temozolomide treatment to radiotherapy or the addition of temozolomide treatment after completion of radiotherapy will improve the results of the treatment.

Status: Accepting New Patients
Principal Investigator: Kumthekar

An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma

The purpose of this research study is to find out whether adding treatment with rindopepimut (also known as CDX-110) to the commonly used chemotherapy drug called temozolomide helps to shrink brain tumors or prevents brain tumors from growing and helps patients with brain tumors live longer than treatment with standard treatment, temozolomide, alone.

Status: Accepting New Patients
Principal Investigator: Raizer

Natural History of Postoperative Cognitive Function, Quality Of Life, and Seizure Control in Patients with Supratentorial Low-Risk Grade II Glioma

The purpose of this study is to understand the effects of a brain tumor and surgery on the participant's cognitive function (thinking abilities, memory), quality of life, and seizures.

Status: Accepting New Patients
Principal Investigator: Raizer

A Phase II Trial of Bevacizumab in Patients with Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy

The purpose of this study is to see what effect bevacizumab, the drug being tested, will have on brain disease from solid tumor cancers. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer.

Status: Accepting New Patients
Principal Investigator: Kumthekar

A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96)(NSC #725085, Alliance IND#15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)

The purpose of this study is to compare what effects, good and/or bad, a vaccine called HSPPC-96 given with a drug called bevacizumab versus bevacizumab alone has on recurrent glioblastoma multiforme (GBM).

Status: Accepting New Patients
Principal Investigator: Raizer

A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy with Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas

The purpose of this study is to determine the effectiveness and safety of combining multiple types of treatments for patients who have recurrent high grade brain tumors.

Status: Accepting New Patients
Principal Investigator: Raizer

Phase I/II Adaptive Randomized Trial of Bevacizumab versus Bevacizumab plus Vorinostat in Adults with Recurrent Glioblastoma (BTTC11-02)

The purpose of this study is to learn if bevacizumab when given with or without vorinostat can help to control malignant gliomas. The safety of these drug combinations will also be studied.

Status: Accepting New Patients
Principal Investigator: Raizer

Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab with or without AMG 386 in Patients with Recurrent Glioblastoma or Gliosarcoma

The purpose of this study is to find out if adding a new investigational drug, AMG 386 to bevacizumab is has a greater effect than bevacizamb alone.

Status: Accepting New Patients
Principal Investigator: Raizer

Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine & Cytarabine with and without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma

This is a randomized investigational study is to determine the effects, good and/or bad, of the combination of low-dose whole brain radiation plus chemotherapy on PCNSL (Primary Central Nervous System Lymphoma) and tumor versus chemotherapy alone.

Status: Accepting New Patients
Principal Investigator: Raizer

Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma

The two main reasons this research study is being done are to see if: •Patients improve if they get treatment with the combination of both radiation therapy and temozolomide chemotherapy as compared to patients who receive treatment with radiation therapy alone. •Patients treated with temozolomide therapy alone (no radiation therapy) have a better or worse quality of life than those patients who are treated with either the combination of radiation therapy and temozolomide or radiation therapy alone.

Status: Accepting New Patients
Principal Investigator: Kumthekar

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 in Combination with Radiation Plus Temozolomide or Temozolomide Alone for Subjects with Glioblastoma Multiforme

The purpose of this study is to study the safety of the study drug (ABT-414), to find highest safe dose of the study drug, and to study how a patient's body handles this new drug in combination with radiation and temozolomide or in combination with temozolomide alone.

Status: Accepting New Patients
Principal Investigator: Kumthekar

A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients with Recurrent High-Grade Glioma

The main purpose of this research study is to see if an investigational drug, ANG1005, can shrink tumor cells in patients with high-grade glioma. Another purpose of this study is to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of ANG1005 in patients.

Status: Accepting New Patients
Principal Investigator: Kumthekar

Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis

There are 2 parts to this study (phase II and phase III). The part of the study in which a participant is enrolled depends on the timing of starting in the study. The purpose of the phase II part of the study is to treat the cancer that has spread to a participant's spine, and is causing pain, with image-guided radiosurgery/SBRT. The purpose of phase III is to compare the effects, good and/or bad, of image-guided radiosurgery/SBRT to standard radiation therapy to find out which treatment provides the most rapid pain relief with the least side effects.

Status: Accepting New Patients
Principal Investigator: Kalapurakal

Phase Ib/II multicenter study of buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma multiforme (GBM)

There are two purposes for this study. The purpose of the first phase of this study is to determine the highest safe dose of buparlisib given in combination with carboplatin or with lomustine in people with recurrent glioblastoma. The purpose of the second phase of this study is to determine whether, buparlisib given in combination with carboplatin and buparlisib given in combination with lomustine compared to lomustine alone, is effective and safe for patients in recurrent glioblastoma.

Status: Accepting New Patients
Principal Investigator: Raizer

A Phase I-II trial Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas BTTC09-01

This study has two phases. In Phase I, the purpose of this study is to determine the highest safe dose and best schedule for the combination of the study drugs, everolimus and sorafenib, for malignant glioma. In Phase II, the purpose is to evaluate the effect of these drugs on malignant gliomas.

Status: Accepting New Patients
Principal Investigator: Raizer

An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination with Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

The purpose of this research study is to assess the safety and efficacy of PLX3397 (the study drug) in people diagnosed with a type of brain cancer called gliblastoma multiforme (GBM).

Status: Accepting New Patients
Principal Investigator: Raizer

last updated: Thu - August 21, 2014 - 08:46 AM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.